{"id":106799,"date":"2025-10-30T22:29:09","date_gmt":"2025-10-30T22:29:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/106799\/"},"modified":"2025-10-30T22:29:09","modified_gmt":"2025-10-30T22:29:09","slug":"nektar-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-in-london","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/106799\/","title":{"rendered":"Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London"},"content":{"rendered":"

SAN FRANCISCO, Oct. 30, 2025 \/PRNewswire\/ — Nektar Therapeutics\u00a0(Nasdaq: NKTR<\/a>)\u00a0today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.<\/p>\n

Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 \u2013 webcast to be available at 11:00 a.m. Greenwich Mean Time \/ 3:00 a.m. Pacific Time \u2013 link\u00a0here<\/a> <\/p>\n

The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:\u00a0https:\/\/ir.nektar.com\/events-and-presentations\/events<\/a>. A replay of the presentation will be available for 30 days.<\/p>\n

If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.<\/p>\n

About Nektar Therapeutics <\/p>\n

Nektar Therapeutics\u00a0is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.<\/p>\n

Nektar is headquartered in San Francisco, California. For further information, visit http:\/\/www.nektar.com<\/a>\u00a0and follow us on LinkedIn.<\/p>\n

Contact: <\/p>\n

For Investors: <\/p>\n

Vivian Wu\u00a0of\u00a0Nektar Therapeutics
628-895-0661<\/p>\n

For Media: <\/p>\n

Jonathan Pappas
LifeSci Communications
857-205-4403
[email\u00a0protected]<\/a>\u00a0<\/p>\n

SOURCE Nektar Therapeutics<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"SAN FRANCISCO, Oct. 30, 2025 \/PRNewswire\/ — Nektar Therapeutics\u00a0(Nasdaq: NKTR)\u00a0today announced that company management will be webcasting its…\n","protected":false},"author":2,"featured_media":106800,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[304,114,22838,85,46,22839,33451],"class_list":["post-106799","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-biotechnology","tag-business","tag-health-care-hospitals","tag-il","tag-israel","tag-medical-pharmaceuticals","tag-nektar-therapeutics"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/106799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=106799"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/106799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/106800"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=106799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=106799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=106799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}